InMed Pharmaceuticals (INM) Restructuring Costs (2022 - 2024)

InMed Pharmaceuticals' Restructuring Costs history runs 3 years deep, the most recent figure standing at $23282.0 for Q2 2024.

• On a quarterly basis, Restructuring Costs rose 128.69% year-over-year to $23282.0 in Q2 2024; TTM through Jun 2024 was -$37961.0, a N/A change from a year earlier, with the FY2024 full-year figure at $80513.0, up 42.73% from the prior year.
• Restructuring Costs improved to $23282.0 in Q2 2024 per INM's latest filing, from $9768.0 in the prior quarter.
• Across five years, Restructuring Costs topped out at $44042.0 in Q4 2022 and bottomed at -$81147.0 in Q2 2023.
• The 3-year median for Restructuring Costs is $16709.0 (2023), against an average of $5753.8.
• Across the five-year window, Restructuring Costs tumbled 76.99% in 2023 and soared 128.69% in 2024, its largest moves.
• Year by year, Restructuring Costs stood at $44042.0 in 2022, then tumbled by 76.99% to $10136.0 in 2023, then soared by 129.7% to $23282.0 in 2024.
• Per Business Quant, the three latest INM Restructuring Costs figures stand at $23282.0 (Q2 2024), $9768.0 (Q1 2024), and $10136.0 (Q4 2023).